US2005095633A1PendingUtilityA1
Novel regulators of fungal gene expression
Assignee: MICROBIA INC A DELAWARE CORPPriority: Dec 22, 2000Filed: Sep 28, 2004Published: May 5, 2005
Est. expiryDec 22, 2020(expired)· nominal 20-yr term from priority
Inventors:Brian CaliDouglas HoltzmanJeffrey C. SilvaJoshua TrueheartLixin ZhangKevin T. MaddenG. Todd MilneAmir Sherman
C07K 14/38C07K 14/385
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to regulators of fungal gene expression and their use in commercial and medical applications. More particularly, the invention relates to regulators of fungal genes involved in production of enzymes, secondary metabolites and other useful products, as well as to regulators of genes involved in fungal invasion. The invention provides novel regulators of fungal gene expression, and methods for using regulator genes in commercial and medical applications.
Claims
exact text as granted — not AI-modified1 - 68 . (canceled).
69 . An isolated nucleic acid molecule comprising a nucleic sequence encoding a polypeptide that when compared to SEQ ID NO:8 (residues 1-315) using BLASTP with the default parameters elicits an E score that is less than 1 e −5.
70 . The isolated nucleic acid molecule of claim 69 , wherein the isolated nucleic acid molecule encodes a protein that increases FLO11 expression when expressed in S. cerevisiae.
71 . A method for increasing expression of a secondary metabolite in a fungal cell, the method comprising transforming the fungal cell with the isolated nucleic acid molecule of claim 69 .
72 . The method of claim 71 , wherein the isolated nucleic acid molecule encodes a protein that increases FL11 expression when expressed in S. cerevisiae.
73 . The method of claim 71 , wherein the secondary metabolite is a polyketide.
74 . The method of claim 71 , wherein the secondary metabolite is a polysaccharide.
75 . The method of claim 71 , wherein the secondary metabolite is mevalonic acid.
76 . The method of claim 71 , wherein the secondary metabolite is lovastatin.
77 . The method of claim 71 , wherein the secondary metabolite is penicillin.
78 . A method for producing a secondary metabolite comprising:
(a) providing a cell that has been transformed with the isolated nucleic acid molecule of claim 69; (b) culturing the cells; and (c) isolating the secondary metabolite from the cultured cells or the culture medium.
79 . A purified polypeptide encoded by the isolated nucleic acid molecule of claim 69 .
80 . A vector comprising the isolated nucleic acid molecule of claim 69 .
81 . The vector of claim 81 , wherein the vector is a fungal expression vector.
82 . An isolated cell harboring the isolated nucleic acid molecule of claim 69 .
83 . An isolated cell harboring the vector of claim 80 .
84 . The isolated cell of claim 82 or 83 , wherein the cell is a fungal cell.
85 . A method for producing a secondary metabolite comprising:
(a) providing a cell that has been transformed with the vector of claim 80; (b) culturing the cells; and (c) isolating the secondary metabolite from the cultured cells or the culture medium.
86 . A method for producing a secondary metabolite comprising:
(a) providing a cell that has been transformed with the vector of claim 81; (b) culturing the cells; and (c) isolating the secondary metabolite from the cultured cells or the culture medium.Join the waitlist — get patent alerts
Track US2005095633A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.